Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2003

View Archived Issues

Chiron acquires rights to aerosolized ciclosporin from Novartis

Methods of detecting and treating cancer based on the Septin9 (MSF) gene

Bridged ketolides designed at Enanta to overcome bacterial resistance

New data suggest a role for statins in the treatment of Alzheimer's disease

ALA reported to improve neuropathic symptoms in diabetes

Procter & Gamble describes new inhibitors of cytokine production

Tyrosine kinase inhibitors and their use in cancer, angiogenesis, etc., claimed by Allergan

Yissum patent covers new agents for cancer, lipid storage disorders

Novel tryptase inhibitors under study at Boehringer Ingelheim

Cannabinoid CB1 antagonists in early development at Solvay

BMS researchers discover new inhibitors of MMP, TACE and/or aggrecanase

U.S./Japanese group identifies elastase release inhibitors

Erythromycin antibiotics prepared and tested at Ortho-McNeil

Novartis claims novel ACE/NEP inhibitors with utility in hypertension therapy

Teijin and Kyorin abandon business integration plans

Preliminary results from phase III trial of RSR-13 in brain metastases

Phase III RESIST trials begin for tipranavir

FDA approves Enteryx technology for GERD

Liprostin trial planned in critical limb ischemia and intermittent claudication

Indevus licenses rights to aminocandin

Cinacalcet demonstrates efficacy in dialysis patients with elevated parathyroid hormone

Enrollment completed in phase II study of ThGRF

Texas Biotechnology acquires Icos interest in partnership

NIH licensing opportunity: methods of inhibiting amino acid formation and tumor angiogenesis

Benzoylalkylindolepyridinium compounds for HIV available from NIH

Potential new immunosuppressant for use in transplantation isolated from Chinese herbs

Another major launch announced for Crestor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...